Abbott to spin off Nutrition unit into independent public company by late 2027

Abbott Laboratories announced that it will separate its Nutrition business, which includes brands such as Ensure, Similac and PediaSure, into a stand‑alone publicly traded company by the end of 2027. The spin‑off is expected to create a new entity with about 16,000 employees, 14 manufacturing sites and roughly $8.5 billion of annual sales. In the same release the company reported third‑quarter 2026 sales up 14.5% year‑over‑year and adjusted earnings of $1.42 per share, while reaffirming its full‑year adjusted EPS guidance of $5.50‑$5.55.

The separation could unlock value by allowing each company to focus on its core markets, and the unchanged EPS guidance signals that the spin‑off will not affect Abbott’s 2026 earnings outlook (the company reaffirmed the guidance in its Q3 release). Investors will need to assess the valuation of both the parent and the new Nutrition entity once the spin‑off is completed.

  • 1Abbott plans to spin off its Nutrition business into an independent, publicly traded company by late 2027.
  • 2The Nutrition unit is projected to generate $8.5 billion in annual sales.
  • 3The new Nutrition company will have approximately 16,000 employees and 14 manufacturing sites.
  • 4Third‑quarter 2026 reported sales grew 14.5% on a reported basis and 7.0% on a comparable basis.
  • 5Adjusted diluted EPS for Q3 2026 was $1.42.
  • 6Abbott reaffirmed its full‑year 2026 adjusted diluted EPS guidance range of $5.50 to $5.55.

Sources